Prospective Grant of Exclusive License: Development of a Companion Diagnostic Kit To Detect Asparagine Synthetase Expression Levels as a Method To Screen for the Drug Efficacy in Treatments for Pancreatic Cancer, Ovarian Cancer, and Multiple Myeloma

Samenvatting

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application No. 12/281,589 and PCT Application No. PCT/US07/ 05555 entitled "Materials and Methods Directed to Asparagine Synthetase and Asparaginase Therapies" (HHS Ref. No. E-132-2006/2), to the French-based ERYtech Pharma LLC which is located in Lyon, France (with an additional office in Philadelphia, Pennsylvania). The patent rights in this invention have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be for to the use of the Licensed Patent Rights limited to a FDA-approved companion diagnostic test predictive of L- asparaginase therapeutic effect in the treatment of pancreatic cancer, ovarian cancer, and multiple myeloma as claimed in the Licensed Patent Rights.